

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN 复星
復星國際有限公司
FOSUN INTERNATIONAL LIMITED
(Incorporated in Hong Kong with limited liability)
(Stock Code: 00656)

**CHANGE OF DIRECTORS AND EXECUTIVE POSITIONS
AND
CHANGE OF THE COMPOSITION OF
BOARD COMMITTEES**

The Board announces the following change of directors and executive positions and change of the composition of Board committees of the Company:

1. Mr. Wang Qunbin, an Executive Director of the Company, has been re-designated as the Co-Chairman of the Company and has ceased to be the CEO of the Company;
2. Mr. Chen Qiyu, an Executive Director of the Company, has been re-designated as the Co-CEO of the Company and has ceased to be the Co-President of the Company;
3. Mr. Xu Xiaoliang, an Executive Director of the Company, has been re-designated as the Co-CEO of the Company and has ceased to be the Co-President of the Company;
4. Mr. Gong Ping, an Executive Director of the Company, has been appointed as the CFO of the Company and has ceased to be the CEO of Fosun Hive; Mr. Xue Linnan has ceased to be the CFO of the Company and has been re-designated as the Vice Chairman of Fosun Hive;
5. Mr. Zhang Houlin, the Senior Vice President of the Company, and Mr. Zhang Ligang, the General Manager of Financial Management Department of the Company, have been appointed as the Co-CFOs of the Company;
6. Mr. Yang Chao has resigned as an Independent Non-Executive Director, the Chairman of the ESG Committee and a member of the Audit Committee, Remuneration Committee and Nomination Committee of the Company due to his age; and
7. Dr. Lee Kai-Fu, an Independent Non-Executive Director of the Company, has been appointed as the Chairman of the ESG Committee of the Company.

The above-mentioned changes and appointments have become effective from 21 February 2020.

The board of directors (the “**Board**”) of Fosun International Limited (the “**Company**”) announces the following change of directors and executive positions and change of the composition of Board committees of the Company:

1. Mr. Wang Qunbin (“**Mr. Wang**”), an Executive Director of the Company, has been re-designated as the Co-Chairman of the Company and has ceased to be the Chief Executive Officer (the “**CEO**”) of the Company;
2. Mr. Chen Qiyu (“**Mr. Chen**”), an Executive Director of the Company, has been re-designated as the Co-CEO of the Company and has ceased to be the Co-President of the Company;
3. Mr. Xu Xiaoliang (“**Mr. Xu**”), an Executive Director of the Company, has been re-designated as the Co-CEO of the Company and has ceased to be the Co-President of the Company;
4. Mr. Gong Ping (“**Mr. Gong**”), an Executive Director of the Company, has been appointed as the Chief Financial Officer (the “**CFO**”) of the Company and has ceased to be the CEO of Fosun Hive; Mr. Xue Linnan has ceased to be the CFO of the Company and has been re-designated as the Vice Chairman of Fosun Hive;
5. Mr. Zhang Houlin, the Senior Vice president of the Company, and Mr. Zhang Ligang, the General Manager of Financial Management Department of the Company, have been appointed as the Co-CFOs of the Company;
6. Mr. Yang Chao (“**Mr. Yang**”) has resigned as an Independent Non-Executive Director, the Chairman of the Environmental, Social and Governance Committee (the “**ESG Committee**”) and a member of the Audit Committee, Remuneration Committee and Nomination Committee of the Company due to his age; and
7. Dr. Lee Kai-Fu, an Independent Non-Executive Director of the Company, has been appointed as the Chairman of the ESG Committee of the Company.

The above-mentioned changes and appointments have become effective from 21 February 2020.

Resignation of Mr. Yang

Mr. Yang has resigned as an Independent Non-Executive Director, the Chairman of the ESG Committee and a member of the Audit Committee, Remuneration Committee and Nomination Committee of the Company with effect from 21 February 2020 due to his age.

Mr. Yang has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”).

The Board would like to express its sincere gratitude to Mr. Yang for his valuable efforts and contributions to the Company during his tenure of office.

Details of directors with change of executive positions

Mr. Wang

Wang Qunbin, aged 50, is an Executive Director and Co-Chairman of the Company. Mr. Wang is the founder of the Company and its subsidiaries (the “**Group**”) and has been a director of various companies within the Group since 1994. Mr. Wang was a director of Shanghai Yuyuan Tourist Mart (Group) Co., Ltd. (listed on the Shanghai Stock Exchange with stock code 600655, (“**Yuyuan**”)) and Henan Lingrui Pharmaceutical Co., Ltd. (listed on the Shanghai Stock Exchange with stock code 600285) and a non-executive director of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (listed on the Hong Kong Stock Exchange with stock code 02196 and the Shanghai Stock Exchange with stock code 600196, (“**Fosun Pharma**”)) and Sinopharm Group Co., Ltd. (listed on the Hong Kong Stock Exchange with stock code 01099, (“**Sinopharm**”)). Mr. Wang was awarded “Asia Pacific Outstanding Entrepreneur Awards” by Enterprise Asia and “Best Asian Corporate Director” at the Asian Excellence Recognition Awards by *Corporate Governance Asia*, etc., and was named one of “China’s 50 Top-performing Corporate Leaders” by *Harvard Business Review*. Mr. Wang received a bachelor’s degree in genetic engineering from Fudan University in 1991.

As at the date of this announcement, Mr. Wang has 5,000 shares of Fosun International Holdings Ltd., representing approximately 14.71% of its issued shares. Fosun International Holdings Ltd. is the beneficial owner of the total issued shares of Fosun Holdings Limited, and Fosun Holdings Limited owns approximately 70.80% equity interest in the Company; Mr. Wang also has 114,075 A shares of Fosun Pharma, representing approximately 0.01% of its issued A shares.

Save as disclosed above, Mr. Wang does not hold any other directorship in any listed public company which securities are listed on any securities market in Hong Kong or overseas during the period of three years preceding the date of this announcement. Save as disclosed above, as at the date of this announcement, Mr. Wang (1) does not hold any position within the Company or other major members of the Group; (2) does not have any relationships with any other directors, senior management, substantial or controlling shareholders of the Company; (3) does not have, and/or is not deemed to have, any interests or short positions in any shares, underlying shares or debentures of the Company or its associated corporations (as defined under Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong); and (4) does not have other major appointments and professional qualifications.

Mr. Wang has entered into a service contract with the Company with a fixed term of services for 3 years commencing from 28 March 2018, and is subject to retirement by rotation and re-election at the annual general meeting in accordance with the Company's articles of association. Mr. Wang is entitled to a remuneration of RMB4,700,000 per annum which is determined by the Board taking reference to his duties and responsibilities and the Company's remuneration policy, and is subject to certain adjustments (if any) as determined by the Board. He is also entitled to an annual discretionary bonus determined by the internal regulation of the Company.

Save as disclosed above, there are no other matters which need to be brought to the attention of the shareholders of the Company regarding the change of executive positions of Mr. Wang nor is there any other information required to be disclosed pursuant to Rule 13.51(2) (h) to (v) of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (the "**Listing Rules**").

Mr. Chen

Chen Qiyu, aged 47, is an Executive Director and Co-CEO of the Company. Mr. Chen joined the Group in 1994. As at the date of this announcement, he has also been an executive director and chairman of Fosun Pharma, a non-executive director and chairman of Shanghai Henlius Biotech, Inc. (listed on the Hong Kong Stock Exchange with stock code 02696), a non-executive director and vice chairman of Sinopharm, a non-executive director of BabyTree Group (listed on the Hong Kong Stock Exchange with stock code 01761), a co-chairman of New Frontier Health Corporation (listed on the New York Stock Exchange with stock code NFH), and a director of Beijing Sanyuan Foods Co., Ltd. (listed on the Shanghai Stock Exchange with stock code 600429) and various companies within the Group. Mr. Chen was a director of Dian Diagnostics Group Co., Ltd. (listed on the Growth Enterprise Market Board of the Shenzhen Stock Exchange with stock code 300244) and Maxigen Biotech Inc. (listed on the Taiwan Stock Exchange with stock code 1783). As at the date of this announcement, Mr. Chen has been the chairman of China Medical Pharmaceutical Material Association, a vice chairman of China Pharmaceutical Innovation and Research Development Association, the honorary chairman and chief

supervisor of Shanghai Biopharmaceuticals Industry Association, the vice council chairman of Shanghai Society of Genetics and a member of the 13th Shanghai Standing Committee of the Chinese People's Political Consultative Conference. Mr. Chen was a member of the 12th Shanghai Standing Committee of the Chinese People's Political Consultative Conference. Mr. Chen was awarded "Shanghai Excellent Constructor of Socialism with Chinese Characteristics from Non-public Sector" and "Shanghai Outstanding Entrepreneur 2018". Mr. Chen received a bachelor's degree in genetics from Fudan University in 1993 and an EMBA degree from China Europe International Business School in 2005.

As at the date of this announcement, Mr. Chen has and is deemed to have 17,418,000 shares of the Company, representing approximately 0.20% of its issued shares; Mr. Chen has 114,075 A shares of Fosun Pharma, representing approximately 0.01% of its issued A shares; Mr. Chen also has 1,478 shares of Fosun Tourism Group ("FTG"), representing approximately 0.00012% of its issued shares.

Save as disclosed above, Mr. Chen does not hold any other directorship in any listed public company which securities are listed on any securities market in Hong Kong or overseas during the period of three years preceding the date of this announcement. Save as disclosed above, as at the date of this announcement, Mr. Chen (1) does not hold any position within the Company or other major members of the Group; (2) does not have any relationships with any other directors, senior management, substantial or controlling shareholders of the Company; (3) does not have, and/or is not deemed to have, any interests or short positions in any shares, underlying shares or debentures of the Company or its associated corporations (as defined under Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong); and (4) does not have other major appointments and professional qualifications.

Mr. Chen has entered into a service contract with the Company with a fixed term of services for 3 years commencing from 28 March 2018, and is subject to retirement by rotation and re-election at the annual general meeting in accordance with the Company's articles of association. Mr. Chen is entitled to a remuneration of RMB4,200,000 per annum which is determined by the Board taking reference to his duties and responsibilities and the Company's remuneration policy, and is subject to certain adjustments (if any) as determined by the Board. He is also entitled to an annual discretionary bonus determined by the internal regulation of the Company.

Save as disclosed above, there are no other matters which need to be brought to the attention of the shareholders of the Company regarding the change of executive positions of Mr. Chen nor is there any other information required to be disclosed pursuant to Rule 13.51(2) (h) to (v) of the Listing Rules.

Mr. Xu

Xu Xiaoliang, aged 47, is an Executive Director and Co-CEO of the Company. Mr. Xu joined the Group

in 1998, and as at the date of this announcement, he has also been the chairman of Fosun Hive and Yuyuan, a non-independent director of Hainan Mining Co., Ltd. (listed on the Shanghai Stock Exchange with stock code 601969), a non-executive director of Fosun Pharma, a non-executive director and vice chairman of Zhaojin Mining Industry Co., Ltd. (listed on the Hong Kong Stock Exchange with stock code 01818), and a director of Shanghai Resource Property Consulting Co., Ltd. (listed on the National Equities Exchange and Quotations (the “NEEQ”) with stock code 833517, (“**Resource Property**”)), Shanghai Foyo Culture & Entertainment Co., Ltd. (listed on the NEEQ with stock code 831472) and various companies within the Group. Mr. Xu was a non-executive director of Shanghai Zendai Property Limited (listed on the Hong Kong Stock Exchange with stock code 00755, (“**Shanghai Zendai**”)). As at the date of this announcement, Mr. Xu has been a deputy to the 15th Shanghai Municipal People’s Congress, the chairman of the Shanghai International Fashion Federation, the co-chairman of Industry-City Integration Development Federation of The Zhejiang Chamber of Commerce, Shanghai. Mr. Xu was awarded the “Shanghai 4 May Youth Medal” and “Shanghai Top Ten Youth Business People”. Mr. Xu received a master’s degree in business administration from the East China Normal University in 2002 and received an EMBA degree from Fudan University in 2019.

As at the date of this announcement, Mr. Xu has and is deemed to have 14,985,000 shares of the Company, representing approximately 0.18% of its issued shares; Mr. Xu also has 2,328 shares of FTG, representing approximately 0.00019% of its issued shares.

Save as disclosed above, Mr. Xu does not hold any other directorship in any listed public company which securities are listed on any securities market in Hong Kong or overseas during the period of three years preceding the date of this announcement. Save as disclosed above, as at the date of this announcement, Mr. Xu (1) does not hold any position within the Company or other major members of the Group; (2) does not have any relationships with any other directors, senior management, substantial or controlling shareholders of the Company; (3) does not have, and/or is not deemed to have, any interests or short positions in any shares, underlying shares or debentures of the Company or its associated corporations (as defined under Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong); and (4) does not have other major appointments and professional qualifications.

Mr. Xu has entered into a service contract with the Company with a fixed term of services for 3 years commencing from 28 March 2018, and is subject to retirement by rotation and re-election at the annual general meeting in accordance with the Company’s articles of association. Mr. Xu is entitled to a remuneration of RMB4,200,000 per annum which is determined by the Board taking reference to his duties and responsibilities and the Company’s remuneration policy, and is subject to certain adjustments (if any) as determined by the Board. He is also entitled to an annual discretionary bonus determined by the internal regulation of the Company.

Save as disclosed above, there are no other matters which need to be brought to the attention of the shareholders of the Company regarding the change of executive positions of Mr. Xu nor is there any other information required to be disclosed pursuant to Rule 13.51(2) (h) to (v) of the Listing Rules.

Mr. Gong

Gong Ping, aged 44, is an Executive Director, Senior Vice President and CFO of the Company. Mr. Gong joined the Group in 2011 and as at the date of this announcement, he has also been the chairman of Paris Realty Fund SA (listed on the Euronext Paris with stock code PAR), the vice chairman of Yuyuan, a non-executive director of Shanghai Zendai, a director of Resource Property and various companies within the Group. As at the date of this announcement, Mr. Gong has been a council member of Shanghai Association for Youth Entrepreneurship and Employment and vice chairman of Shanghai Youth Entrepreneurs Association. He used to serve as a senior assistant to president of the Group, and the general manager of Corporate Development Department. Prior to joining the Group, Mr. Gong worked at Pudong branch and the headquarters of Bank of Shanghai as well as the PRC headquarters of Standard Chartered Bank. Mr. Gong also served as a global strategist at the headquarters of Samsung Group in Korea, carrying out special assignments across various sectors including financial services, technology and real estate worldwide. Mr. Gong graduated from Fudan University in 1998 with a bachelor's degree in international finance, and then obtained his master's degree in finance from Fudan University in 2005. Mr. Gong also received his master's degree in business administration from International Institute for Management Development (IMD) in Lausanne, Switzerland in 2008.

As at the date of this announcement, Mr. Gong has and is deemed to have 9,935,000 shares of the Company, representing approximately 0.12% of its issued shares; Mr. Gong also has 988 shares of FTG, representing approximately 0.00008% of its issued shares.

Save as disclosed above, Mr. Gong does not hold any other directorship in any listed public company which securities are listed on any securities market in Hong Kong or overseas during the period of three years preceding the date of this announcement. Save as disclosed above, as at the date of this announcement, Mr. Gong (1) does not hold any position within the Company or other major members of the Group; (2) does not have any relationships with any other directors, senior management, substantial or controlling shareholders of the Company; (3) does not have, and/or is not deemed to have, any interests or short positions in any shares, underlying shares or debentures of the Company or its associated corporations (as defined under Part XV of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong); and (4) does not have other major appointments and professional qualifications.

Mr. Gong has entered into a service contract with the Company with a fixed term of services for 3 years commencing from 28 March 2018, and is subject to retirement by rotation and re-election at the annual

general meeting in accordance with the Company's articles of association. Mr. Gong is entitled to a remuneration of RMB3,000,000 per annum which is determined by the Board taking reference to his duties and responsibilities and the Company's remuneration policy, and is subject to certain adjustments (if any) as determined by the Board. He is also entitled to an annual discretionary bonus determined by the internal regulation of the Company.

Save as disclosed above, there are no other matters which need to be brought to the attention of the shareholders of the Company regarding the appointment of Mr. Gong nor is there any other information required to be disclosed pursuant to Rule 13.51(2) (h) to (v) of the Listing Rules.

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

21 February 2020

As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Qin Xuetao and Mr. Gong Ping; the non-executive director is Ms. Chen Shucui; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang and Dr. Lee Kai-Fu.